Found: 21
Select item for more details and to access through your institution.
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
- Published in:
- Current Oncology, 2021, v. 28, n. 2, p. 1056, doi. 10.3390/curroncol28020103
- By:
- Publication type:
- Article
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Alternative Medicine and the Ethics Of Commerce.
- Published in:
- Bioethics, 2016, v. 30, n. 2, p. 77, doi. 10.1111/bioe.12226
- By:
- Publication type:
- Article
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. e2225118, doi. 10.1001/jamanetworkopen.2022.25118
- By:
- Publication type:
- Article
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. 1, doi. 10.1001/jamanetworkopen.2022.25118
- By:
- Publication type:
- Article
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 11, p. e2133388, doi. 10.1001/jamanetworkopen.2021.33388
- By:
- Publication type:
- Article
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
- Published in:
- JNCI Cancer Spectrum, 2022, v. 6, n. 4, p. 1, doi. 10.1093/jncics/pkac047
- By:
- Publication type:
- Article
Impact of rarity on Canadian oncology health technology assessment and funding.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
- Published in:
- Breast Cancer Research & Treatment, 2016, v. 157, n. 3, p. 535, doi. 10.1007/s10549-016-3823-y
- By:
- Publication type:
- Article
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces.
- Published in:
- MDM Policy & Practice, 2021, v. 6, n. 1, p. 1, doi. 10.1177/23814683211021060
- By:
- Publication type:
- Article
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 10, p. 11451, doi. 10.1002/cam4.5862
- By:
- Publication type:
- Article
Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
- Published in:
- Cancer Medicine, 2020, v. 9, n. 1, p. 215, doi. 10.1002/cam4.2704
- By:
- Publication type:
- Article
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 1, p. 160, doi. 10.1002/cam4.2705
- By:
- Publication type:
- Article
Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 8, p. 1910, doi. 10.1002/ijc.33357
- By:
- Publication type:
- Article
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-586
- By:
- Publication type:
- Article
The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada.
- Published in:
- Current Oncology, 2024, v. 31, n. 6, p. 3591, doi. 10.3390/curroncol31060264
- By:
- Publication type:
- Article
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
- Published in:
- Current Oncology, 2024, v. 31, n. 4, p. 1876, doi. 10.3390/curroncol31040141
- By:
- Publication type:
- Article
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer.
- Published in:
- Current Oncology, 2024, v. 31, n. 3, p. 1633, doi. 10.3390/curroncol31030124
- By:
- Publication type:
- Article
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
- Published in:
- 2014
- By:
- Publication type:
- journal article